Business Context and Reporting Period
Evogene Ltd. filed Form 6-K on August 31, 2022, to report financial results for the second quarter ended June 30, 2022. The filing incorporates a press release (Exhibit 99.1) detailing these results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1) but are not explicitly stated in the Form 6-K body text provided.
Material Changes and Corporate Actions
- Nasdaq Compliance: Evogene regained compliance with the Nasdaq minimum closing bid price rule.
- Shareholder Meeting Update: Consequently, the proposal for a reverse share split (matter number 2) was removed from the agenda for the General Meeting of shareholders.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, or risk factors. The press release incorporated by reference excludes statements from the President and CEO regarding forward-looking information for the purpose of registration statements.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2022 financial figures (revenue, net loss, cash position).
- Confirm the current status of the shareholder meeting agenda regarding the reverse share split.
- Verify the company's ongoing compliance with Nasdaq listing standards.